Amgen presents new data on Kyprolis in multiple myeloma
7 December 2015 | By Victoria White
The data showed Kyprolis in combination with dexamethasone significantly extended disease progression compared to bortezomib plus dexamethasone...
List view / Grid view
News
Astellas announces updated results for gilteritinib in AML
7 December 2015 | By Victoria White
This updated analysis of the Phase 1/2 study included 169 patients with FLT3 mutations who were treated with at least 80 mg gilteritinib (ASP2215)...
Novo Nordisk submits MAA for faster-acting insulin aspart
4 December 2015 | By Victoria White
Faster-acting insulin aspart is a mealtime insulin for improved control of postprandial glucose excursions and has been developed for the treatment of people with type 1 and type 2 diabetes...
Amgen submits MAA for biosimilar ABP 501 to the EMA
4 December 2015 | By Victoria White
Amgen believes this submission is the first adalimumab biosimilar application submitted to the EMA and represents Amgen's first biosimilar to be submitted for approval in the EU...
Continued and on-going process verification
3 December 2015 | By ChemAcademy
The FDA and EU published a lot of guidlines regarding process validation which makes it hard to keep up with all the changes...
Global COPD treatment market to hit $11.2 billion by 2021, says GBI Research
3 December 2015 | By Victoria White
GBI Research says the market will rise at a steady CAGR of 2.9% from $9.2 billion in 2014 to $11.2 billion in 2021...
TxCell reacquires full rights to Ovasave from Trizell
3 December 2015 | By Victoria White
TxCell has agreed with Trizell to terminate the collaboration, option, development and license agreement concerning TxCell’s lead product Ovasave...
Cytos Biotechnology and Kuros Biosurgey to combine
3 December 2015 | By Victoria White
The combined company has an attractive late stage pipeline and several products at preclinical stage...
NICE says ‘no’ to asfotase alfa in draft guidance
3 December 2015 | By Victoria White
NICE has published draft guidance as part of its highly specialised technologies programme that does not recommend Alexion’s asfotase alfa for treating paediatric-onset hypophosphatasia...
J&J announces new global commitments to end HIV infection in girls and women
2 December 2015 | By Victoria White
Johnson & Johnson has announced four new public-private partnerships to significantly reduce the burden of HIV incidence, especially among adolescent girls...
Second cohort of NKG2D CAR T-Cell Phase I Trial commences
2 December 2015 | By Victoria White
Celyad has announced the infusion of the first patient of the second cohort of its Phase I clinical trial evaluating it's NKG2D CAR T-Cell therapy in acute myeloid leukaemia and multiple myeloma...
Trulicity effective as add-on treatment to sulfonylurea in study
New data from a completed Phase 3 trial show Lilly’s Trulicity (dulaglutide) 1.5 mg plus a sulfonylurea was significantly more effective than a sulfonylurea alone in lowering haemoglobin A1c (A1C) from baseline after 24 weeks of treatment.
Victoza provides greater glycaemic control than SGLT-2 inhibitors
2 December 2015 | By Victoria White
Novo Nordisk has released new data that shows Victoza (liraglutide) provides a greater HbA1c reduction and an improved likelihood of reaching glycaemic goals compared to sodium-glucose cotransporter 2 inhibitors...
Join CI Precision and PT Electronics PVT Ltd at P-MEC India in Mumbai, 1 – 3 Dec 2015
1 December 2015 | By CI Precision
CI Precision and our channel partner PT Electronics are exhibiting at CPhi P-MEC India 2015 in Mumbai on 1-3 December...
Tecan helps Repsol to drive the fuels of the future
1 December 2015 | By Tecan
The Madrid Technology Center of global energy company Repsol relies on two Freedom EVO® platforms for colony picking and enzymatic assays for research into fossil fuel alternatives, using Tecan’s 350 µl nested LiHa disposable tips to achieve extended walkaway times...
